I-Mab
Yahoo Finance • 9 days ago
I-Mab Reports Full Year 2024 Financial Results and Provides Business Update
Continued positive momentum in givastomig Phase 1b combination trial in first-line gastric cancer, with topline dose escalation data (n=17) expected in 2H 2025Enrollment completed ahead of schedule in the first givastomig Phase 1b dose exp... Full story
Yahoo Finance • 22 days ago
I-Mab Announces Receipt Of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
ROCKVILLE, Md., March 21, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (“I-Mab” or the “Company”), announced today that on March 19, 2025 it received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasd... Full story
Yahoo Finance • last month
I-Mab Announces Accelerated Givastomig Phase 1b Study Progress
Enrollment completed ahead of schedule in the first dose expansion cohortMomentum continues with first patient dosed in the second expansion cohortTopline results from the 40-patient dose expansion study expected in 1H 2026 Phase 1b dose e... Full story
Yahoo Finance • 2 months ago
I-Mab to Participate in Leerink Partners Global Healthcare Conference
ROCKVILLE, Md., Feb. 18, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a US-based, global biotech company, exclusively focused on the development of precision immune-oncology agents for the treatment of cancer, today ann... Full story
Yahoo Finance • 2 months ago
I-Mab to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference
ROCKVILLE, Md., Feb. 04, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that... Full story
Yahoo Finance • 10 months ago
I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer
ROCKVILLE, Md., June 6, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for t... Full story
Yahoo Finance • last year
I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023
ROCKVILLE, MD, U.S. and SHANGHAI, China, Nov. 1, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discove... Full story
Yahoo Finance • 3 years ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of I-Mab - IMAB
NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of I-Mab (“I-Mab” or the “Company”) (NASDAQ: IMAB). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.... Full story
Yahoo Finance • 3 years ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of I-Mab - IMAB
NEW YORK, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of I-Mab (“I-Mab” or the “Company”) (NASDAQ: IMAB). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.c... Full story
Yahoo Finance • 3 years ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of I-Mab - IMAB
NEW YORK, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of I-Mab (“I-Mab” or the “Company”) (NASDAQ: IMAB). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw... Full story
Yahoo Finance • 3 years ago
10 52-Week Low Stocks to Buy Now
In this article, we discuss 10 52-week low stocks to buy now. If you want to see more stocks in this selection, check out 5 52-Week Low Stocks to Buy Now. The 52-week low for a stock reflects the least closing price the security has trade... Full story
Yahoo Finance • 3 years ago
I-Mab to Present Phase 2 Clinical Data of CD47 Antibody Lemzoparlimab at ESMO Congress 2022
GAITHERSBURG, Md. and SHANGHAI, July 18, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announc... Full story
